James Quigley
Stock Analyst at Morgan Stanley
(1.68)
# 3,468
Out of 5,138 analysts
25
Total ratings
50%
Success rate
1.08%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $69.54 | +82.63% | 7 | Dec 9, 2025 | |
| NVO Novo Nordisk | Maintains: Buy | $60 → $54 | $62.33 | -13.36% | 1 | Nov 28, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $144.34 | -18.25% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $46.59 | +39.51% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.89 | +18.11% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $33.54 | +19.28% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.61 | +343.21% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $69.54
Upside: +82.63%
Novo Nordisk
Nov 28, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $62.33
Upside: -13.36%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $144.34
Upside: -18.25%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $46.59
Upside: +39.51%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.89
Upside: +18.11%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $33.54
Upside: +19.28%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.61
Upside: +343.21%